ロード中...
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
PURPOSE: To evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of trebananib (AMG 386)—a first-in-class angiopoietin-1/2 antagonist peptide-Fc fusion protein—in Japanese patients, we conducted a phase 1, dose escalation study. METHODS: Eligible patients were men or women, ag...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer-Verlag
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3535401/ https://ncbi.nlm.nih.gov/pubmed/23124648 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-2000-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|